Trials / Completed
CompletedNCT00148382
Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects
Randomized, Double Blind, Parallel Group, Repeat Dose Pharmacokinetic and Pharmacodynamic Study of Four Doses of ATL-962 (40mg, 80mg, 120mg 240mg) in Otherwise-Healthy Obese Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 80 (planned)
- Sponsor
- Alizyme · Industry
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the amount of metabolites of ATL-962 in the blood and to investigate the effect of ATL-962 on the amount of fat that is excreted in the faeces in subjects who are obese
Detailed description
Obesity is a significant and increasing clinical problem. There is a need for effective therapeutic agents to help people reduce weight. ATL-962 is a lipase inhibitor which could reduce the amount of fat absorbed from a person's diet, leading to weight reduction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATL-962 |
Timeline
- Start date
- 2005-04-01
- Completion
- 2005-07-01
- First posted
- 2005-09-08
- Last updated
- 2007-04-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00148382. Inclusion in this directory is not an endorsement.